Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Peripheral edema from MET inhibitors like capmatinib or tepotinib is cumulative and unavoidable over long-term treatment. Dr. Liu notes that diuretics merely elevate creatinine and compression stockings simply displace fluid. Instead of continuing until disease progression, clinicians should reduce doses and implement temporary treatment breaks until swelling recedes to an acceptable baseline, resuming therapy before tumor progression occurs.
Related Insights
Hedgehog inhibitors for basal cell carcinoma cause significant side effects like dysgeusia and muscle cramps. To improve tolerability and long-term adherence, clinicians use practical strategies like scheduled treatment interruptions (e.g., weeks on, weeks off) rather than continuous daily dosing.
When managing side effects from highly effective therapies like MEK inhibitors, it's often better to temporarily hold treatment and then resume at the original dose rather than immediately dose-reducing. This strategy maintains dose intensity, which is critical for maximizing the drug's therapeutic benefit.
To manage Dasatinib's common side effect of pleural effusions, a randomized study showed that skipping doses on weekends is superior to dose reduction. This strategy leverages the drug's short half-life, maintaining peak levels for efficacy while providing a break from off-target effects that cause toxicity.
Despite newer MET TKIs like capmatinib and tipotinib being available, the older drug crizotinib remains a valuable option for NSCLC patients with MET alterations. It is often better tolerated, making it a practical choice for patients who cannot handle the side effects of newer agents.
The investigational drug ABN-401 shows a lower incidence of peripheral edema, a common side effect of MET inhibitors. Its higher specificity for MET, avoiding inhibition of the AXL kinase which is implicated in edema, demonstrates a path toward better-tolerated drugs through rational design.
To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.
A trial investigating intermittent versus continuous axitinib in metastatic RCC addresses a major clinical challenge: the significant toxicity and impaired quality of life from continuous TKI therapy. Proving non-inferiority for an intermittent schedule could fundamentally change patient management and improve long-term tolerability.
Loncastuximab Tesirine (Lanka-T) can cause a unique "third spacing" side effect, leading to significant edema and fluid retention that is resistant to common diuretics like furosemide (Lasix). Spironolactone has proven more effective for managing this specific toxicity, representing a key clinical pearl for nurses and prescribers.
The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.
Effective management of Loncastuximab Teserine (Lanca-T) requires a hands-on, internist-like approach. Clinicians must perform physical exams to detect trace pretibial edema and proactively start spironolactone at the earliest sign. This prevents progression to severe fluid retention, allowing patients to stay on this effective therapy longer.
